





































Circulating Macrophage Activation Markers Predict
Transplant-Free Survival in Patients With Primary
Sclerosing Cholangitis
Lars Bossen, MD1, Mette Vesterhus, MD, PhD2,3,4, Johannes R. Hov, MD, PhD2,5,6,7, Martti Färkkilä, MD, PhD8,
William M. Rosenberg, MA, MBBS, DPhil, FRCP9, Holger J. Møller, MD, PhD, DMSc10, Kirsten M. Boberg, MD, PhD2,5,6,7,
Tom H. Karlsen, MD, PhD2,5,6,7 and Henning Grønbæk, MD, PhD1
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by bile duct
inflammation and fibrosis. The role of macrophages in PSC development and progression is less
studied. Macrophage activationmarkers soluble (s)CD163 andmannose receptor (sMR) are associated
with disease severity and outcome in other liver diseases, but not previously investigated in PSC. We
evaluated sCD163 and sMR regarding disease severity and prognosis in patients with PSC.
METHODS: We investigated 2 independent PSC cohorts from Oslo (n5 138) and Helsinki (n5 159) and analyzed
blood sCD163 and sMR levels. The Mayo score, Enhanced Liver Fibrosis Test, and Amsterdam-Oxford
model were assessed for comparison.
RESULTS: Median (interquartile range) sCD163was 3.32 (2.27–5.60) and 1.96 (1.47–2.70)mg/L in the Oslo and
Helsinki cohorts, respectively, reflecting differences in disease severity between cohorts. Median sMR
was similar in both cohorts, 0.28 (0.22–0.44) and0.28mg/L (0.20–0.36), respectively. In both cohorts,
sCD163and sMR levels raisedwith increasingdisease severity (liver enzymes,Mayo score, and enhanced
liver fibrosis test). Patients with high baseline levels of sCD163 had shorter transplant-free survival than
patients with low baseline levels. Furthermore, sCD163 was associated with transplant-free survival in
univariate cox-regression analyses. Both sCD163 and sMR performed better in the Oslo cohort of more
severely diseased patients than those in the Helsinki cohort of more mildly diseased patients.
DISCUSSION: Macrophage activation markers are elevated according to disease severity suggesting an important role of
macrophages inPSC.Furthermore, sCD163was identifiedasaprognosticmarkerandpredictorof transplant-
free survival in PSC (see Visual Abstract, Supplementary Digital Content 4, http://links.lww.com/CTG/A516).
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INTRODUCTION
Primary sclerosing cholangitis (PSC) is a progressive autoim-
mune liver disease with chronic inflammation and strictures of
intra- and extra-hepatic bile ducts, ultimately leading to fibrosis
and cirrhosis of the liver (1,2). There is no approved pharmaco-
logical treatment, and the only curative option is liver trans-
plantation (LT) (3). A better understanding of disease pathology
and progression and better biomarkers are unmet needs to im-
prove use of surrogate endpoints in the design of clinical trials for
assessment of disease severity, progression, and treatment re-
sponse (4) because these trials suffer from difficulties with low
event rates and hence a low ability to prove effect of a specific
intervention (5).
Macrophages are generally activated in inflammatory liver
diseases and may also play a role in PSC development and pro-
gression. Previous studies showed that the numbers of peri-
sinusoidal macrophages, investigated in liver biopsies, were
higher in patients with PSC than in patients with primary biliary
cholangitis (PBC) and healthy controls (6,7). Furthermore, a re-
cent study showed elevated frequencies of macrophages in the
livers of patients with PSC compared with other liver diseases,
concluding that macrophages may have a potential role in PSC
pathophysiology (8). Recent data also suggest that soluble CD14,
often regarded as a monocyte activation marker, is elevated in
patients with PSC and predicts liver transplantation-free survival
(9). However, others found similar levels of granulocyte-
Table 1. Baseline characteristics of the patients with PSC in the Oslo and Helsinki cohorts
Oslo cohort Helsinki cohort
Tx-free survivors Tx/death P Value Tx-free survivors Tx/death P Value
N 75 63 134 25
Men, n (%) 61 (81.3) 46 (73.0) NS 69 (51.5) 15 (60.0) NS
Age, yr, median (IQR) 36.2 (26.2–47.1) 45.0 (36.0–55.5) ,0.001 42.8 (33.2–54.2) 38.6 (29.8–49.7) NS
Age at diagnosis, yr, median (IQR) 30.9 (23.0–43.4) 38.3 (30.6–52.0) 0.001 36.5 (27–46) 26 (20–37) 0.003
PSC duration, yr, median (IQR) 0.6 (0.0–5.7) 2.7 (0.1–7.7) NS 0.44 (0.28–0.77) 0.69 (0.45-1-14) 0.006
UDCA use at inclusion, n (%) 21 (28.0) 31 (49.2) 0.009 98 (73.1) 14 (56.0) NS
IBD ever, n (%)a 61 (82.4) 41 (65.1) 0.02 97 (72.4) 19 (76.0) NS
Years of follow-up, median (IQR) 7.1 (6.0–7.8) 1.1 (0.3–2.9) ,0.001 8.1 (8.1–8.2) 3.9 (1.5–5.2) ,0.001
Liver transplant, n (%) 0 46 (73) 0 23 (92)
Death as endpoint, n (%) 0 17 (27) 0 2 (8)
Laboratory dataa,b N
ELF test, median (IQR) 9.2 (8.3–10.2) 11.1 (9.7–12.3) ,0.001 159 8.4 (7.4–9.0) 10.3 (8.8–10.9) ,0.001
Mayo risk score, median (IQR) 20.35 (20.97–0.25) 1.13 (0.05–2.58) ,0.001 64 20.43 (20.66–0.01) 0.46 (20.60–0.79) 0.041
AOM, median (IQR) 1.46 (1.15–1.84) 2.38 (1.79–3.00) ,0.001 64 1.52 (1.26–1.76) 1.63 (1.38–2.82) NS
ALP, U/L, median (IQR) 189 (118–282) 286 (197–483) ,0.001 95 97 (72–142) 186 (140–324) ,0.001
ALP, by ULN, median (IQR) 1.8 (1.1–2.7) 2.7 (1.9–4.6) ,0.001 95 0.92 (0.69–1.35) 1.77 (1.33–3.10) ,0.001
AST, U/L, median (IQR) 53 (34–92) 90 (55–165) ,0.001 78 30 (25–40) 48 (32–84) 0.001
ALT, U/L, median (IQR) 70 (45–158) 101 (62–161) NS 97 29 (19–45) 53 (30–100) 0.003
Albumin, g/L, median (IQR) 42 (40–45) 37 (32–42) ,0.001 71 38 (37–40) 37 (33–40) NS
Total bilirubin, mmol/L, median (IQR) 13 (9–24) 34 (16–126) ,0.001 84 11 (8–17) 18 (10–22) NS
Creatinine, mmol/L, median (IQR) 68 (61–73) 61 (54–74) NS 88 67 (56–79) 68 (62–75) NS
Platelets, 109/L, median (IQR) 308 (230–374) 261 (142–345) NS 95 259 (214–305) 265 (134–280) NS
INR, median (IQR) 1.03 (0.96–1.09) 1.05 (0.94–1.25) NS 53 1 (1.0–1.1) 1 (1.0–1.1) NS
Leukocytes, 109/L, median (IQR) 6.3 (4.7–8.1) 6.0 (5.0–7.6) NS 0 — — —
CRP, mg/L, median (IQR) 2.6 (1.3–5.9) 8.9 (3.2–19.0) ,0.001 0 — — —
aRefers to a subpopulation with a few missing data in the Oslo cohort.
bData only available in a number of patients in the Helsinki cohort, see N.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AOM, Amsterdam-Oxford Model for primary sclerosing cholangitis; AST, aspartate aminotransferase; CRP, C-
reactive Protein; ELF, enhanced liver fibrosis; IBD, inflammatory bowel disease; INR, International normalized ratio; IQR, interquartile range; NS, not significant (P$ 0.05);
PSC, primary sclerosing cholangitis; Tx, liver transplantation; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.







macrophage colony-stimulating factor in patients with PSC and
age- and sex-matched controls (10).
The macrophage activation markers soluble (s)CD163
(11,12) and mannose receptor (sMR) (13) are associated with
disease severity inmultiple liver diseases including autoimmune
hepatitis (AIH) and primary biliary cholangitis (14–24). Fur-
thermore, sCD163 and sMR are associated with prognosis in
patients with liver cirrhosis, acute alcoholic hepatitis, and acute-
on chronic liver failure (ACLF) (17,18,25–27). However, mac-
rophage activation markers have not yet been investigated in
patients with PSC. We aimed to investigate the macrophage
activation markers sCD163 and sMR in 2 independent cohorts
of patients with PSC and hypothesized that high levels of
sCD163 and sMR would be associated with more severe liver
disease and worse prognosis.
MATERIALS AND METHODS
Patient population and data collection
The protocol was in accordance with the Declaration of Hel-
sinki and approved by the regional committee for research
ethics in South Eastern Norway (reference number 2011/
2,572) and Helsinki. The patient panels included 138 patients
with large-duct PSC from the Norwegian NoPSC biobank,
collected during 2008–2012, and 159 patients with large-duct
PSC from Helsinki, collected during 2006–2015. Patients were
retrospectively included from 2 research registries (Oslo and
Helsinki) into which patients were enrolled on referral to the 2
respective centers. Referrals in Oslo were mainly for complex
or advanced cases, whereas in Finland, all patients were re-
ferred on diagnosis.
PSC was diagnosed based on typical cholangiographic find-
ings by either magnetic resonance cholangiopancreatography
(MRCP) or endoscopic retrograde cholangiopancreatography
(ERCP) according to acknowledged standard criteria (28,29). The
first pathological cholangiography defined the date of diagnosis of
PSC. PSC duration was defined as the time from the date of
diagnosis to the date of inclusion. Data on sCD163 and sMR and
platelets, creatinine, total bilirubin, albumin, international nor-
malized ratio (INR), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP), and
gamma-glutaryltransferase (GGT) stem from blood samples
taken on the date of inclusion. Data onUDCAuse stems from the
Figure 1. sCD163 and sMRdistribution in 3 prespecified risk groups ofMayo score and ELF test. White boxes to the left are from theOslo cohort, gray boxes
to the right are from the Helsinki cohort. Mayo score is available in 64 patients in the Helsinki cohort, of whom only 2 had aMayo score.2. ELF, enhanced
liver fibrosis; sCD163, soluble CD163; sMR, soluble mannose receptor.
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date of inclusion. Cases of PSC with features of AIH, fulfilling
diagnostic criteria of AIH and PSC (30), were included. Cases of
secondary cholangitis or small duct PSC were excluded.
Mayo risk scores were calculated (31). Serum samples were
also analyzed by the commercially available enhanced liver fi-
brosis (ELF) test (Siemens Healthineers, Tarrytown, NY) using
an ADVIA Centaur XP analyzer (Siemens Healthineers, Tar-
rytown, NY). The prognostic Amsterdam-Oxford Model
(AOM) for PSC was calculated (32). Plasma concentrations of
sCD163 and sMR were measured in duplicate by an in-house
sandwich enzyme-linked immunosorbent assay, as previously
described in samples frozen at 280°C (20,33). Reference in-
tervals for sCD163 is 0.69–3.86 mg/L11 and for sMR 0.10–0.43
mg/L.20 Soluble CD163 and sMR are resistant to repeated
freezing and thawing (20,33).
Patient records and the research database were queried for
information on clinical and laboratory data. Unfortunately, all
data were not available in the Helsinki cohort because of the
retrospective design of this study. Inflammatory bowel disease
(IBD) diagnosis was based on findings at colonoscopy and his-
tology. Updated information on liver transplantation dates and
indications by December 31, 2016, were retrieved from the
Norwegian/Nordic Liver Transplant Registry, and data on all-
cause death by the same date were retrieved from the Norwegian
Death Registry. The Helsinki cohort was updated with events
through August 2018.
Statistical analysis
Statistical analyses were performed using SPSS version 24.0
software (SPSS, Chicago, IL) and Stata version 13 (StataCorp,
Texas). Continuous variables were tested for normal distribution,
and for comparison between groups, the Student t test, theMann-
Whitney U test, or the Kruskal-Wallis test was applied, as ap-
propriate. Biochemical values showing a skewed distribution
were transformed using natural logarithmic transformation. A
composite endpoint composed by all-cause death and LT was
defined. All patients who died in the Oslo cohort, died from PSC-
related cancer. Three groups of disease severity (low, in-
termediate, and high) were defined by Mayo risk score#0,.0 to
,2, and$2. Three groups of fibrosis severity (mild, moderate, and
severe) were defined according to the ELF test level,7.7,$7.7 to
,9.8, and $9.8, respectively, as recommended by the manufac-
turer (34). Follow-up started at the date of inclusion and ended at
the date of reaching the composite endpoint, or, in case, no end-
point was reached, date of the last follow-up. To evaluate the
prognosis, the patients were stratified in 2 groups according to
established upper limit of normal of sCD163 (3.86mg/L) and sMR
(0.43 mg/L), respectively, and 8-year transplant-free survival were
estimated while using the logrank test to compare crude risk.
Correlations between sCD163 and sMR, respectively, and other
laboratory variables were assessed by the Spearman rank correla-
tion test.We usedCox regression to assess the potential association
of sCD163 and sMR with the occurrence of the endpoint while
adjusting for confounding by ELF test and AOM. We did not
include the Mayo score in the regression analysis because of the
large overlap of variables included in the Mayo score and AOM.
We performed an additional Cox regression analysis including a
‘recruitment center’ variable after combining the 2 cohorts while
adjusting for the ELF test andAOM.Weused smoothing splines to
determine the functional form of sCD163 and sMR and the loga-
rithmic values of both variables and included the logarithmic val-
ues in our Cox regression analysis because this gave a more linear
hazard ratio over the range of measured values (see Supplemental
Figure 1, Supplementary Digital Content 1, http://links.lww.com/
CTG/A513). The ability of sCD163 and sMR to discriminate be-
tween patientswho experienced an outcome and thosewhodid not
were determined by computing the area under the receiver oper-
ating characteristic curve. The optimal threshold to distinguish
Figure 2. Cumulative death or LT in patients with low or high sCD163 (left) or sMR (right) in the combined cohort. Cutoffs for sCD163 (3.86mg/L) and sMR
(0.43 mg/L), respectively. The logrank test for equal survivor functions: sCD163, P, 0.001; sMR, P, 0.001. LT, liver transplantation; sCD163, soluble
CD163; sMR, soluble mannose receptor.







patients reaching an endpoint from those who did not was calcu-
lated by the Youden index.
RESULTS
Patients
Patient characteristics fromboth cohorts are described in Table 1.
We included 138 patients with PSC from a well-characterized
Norwegian panel with a median Mayo score of 0.12 (median age
40 years, 78% men). The median follow-up time was 5.4 years
(range, 0.0–8.3), during which 17 patients died and 46 underwent
LT. Eleven patients had features of AIH.
In the Helsinki cohort including 159 patients with PSC, the
median Mayo score was 20.37, median age was 42.2 years, and
53% were men. During a median follow-up time of 8.1 years
(range, 0.1–8.3), 2 patients died and 23 were liver transplanted.
Twelve patients had features of AIH.
Patients in the Oslo cohort had a longer duration of PSC before
inclusion in the study than patients in the Helsinki cohort, were more
oftenmen, lessoftenusedursodeoxycholicacid (UDCA), andhadmore
severe liver disease at inclusion as defined by higher ELF test, Mayo
score, AOM, ALP, and bilirubin levels (see Supplemental Table 1,
Supplementary Digital Content 2, http://links.lww.com/CTG/A514).
sCD163 and sMR levels in patients with PSC
In the Oslo cohort, median levels (interquartile range) of sCD163
and sMR were 3.32 mg/L (2.27–5.60) and 0.28 mg/L (0.22–0.44),
respectively. In theHelsinki cohort,median sCD163was 1.96mg/
L (1.47–2.70) and median sMR was 0.28 mg/L (0.20–0.36).
For correlations between sCD163 and sMR with liver pa-
rameters, we combined the Oslo and Helsinki cohorts and
sCD163 and sMR correlated with ALP, bilirubin, ALT, and al-
bumin (see Supplemental Table 2, Supplementary Digital Con-
tent 3, http://links.lww.com/CTG/A515). Data for the individual
cohorts are shown in supplemental Table 2 (see Supplementary
Digital Content 3, http://links.lww.com/CTG/A515).
Furthermore, sCD163 and sMR increased with increasing
Mayo score, ELF test, andAOMin the combined cohort (Figure 1,
Supplemental Table 2 [see Supplementary Digital Content 3,
http://links.lww.com/CTG/A515]). Data for the individual co-
horts are shown in supplemental Table 2 (see Supplementary
Digital Content 3, http://links.lww.com/CTG/A515).
There was no difference in median sCD163 levels between
patients with or without a diagnosis of IBD (data not shown).
Furthermore, there were no differences in sCD163 levels
between male and female patients with PSC or in patients
Table 2. Univariate Cox regression analyses of factors affecting the transplant-free survival in patients with PSC
Oslo cohort Helsinki cohort Combined cohort
HR 95% CI P Value N HR 95% CI P Value N HR 95% CI P Value N
Mayo score, per point increase 1.94 1.62–2.32 ,0.001 129 2.25 1.26–4.01 0.006 64a 2.11 1.78–2.49 ,0.001 193b
ELF test, per point increase 1.80 1.55–2.08 ,0.001 138 2.23 1.69–2.94 ,0.001 159 2.04 1.80–2.31 ,0.001 297
AOM, per point increase 2.56 1.94–3.37 ,0.001 128 3.07 1.42–6.62 0.004 64a 2.85 2.20–3.69 ,0.001 192c
LnsCD163 3.15 2.19–4.54 ,0.001 138 2.89 1.54–5.44 0.001 159 3.82 2.86–5.11 ,0.001 297
LnsMR 2.92 1.89–4.52 ,0.001 138 1.61 0.70–3.73 0.265 159 2.82 1.88–4.24 ,0.001 297
Age, per year increase 1.04 1.02–1.06 ,0.001 138
Male, yes vs no 0.68 0.39–1.19 0.177 138
Age at diagnosis, per year increase 1.03 1.01–1.05 ,0.001 138
PSC duration, per year increase 1.03 0.99–1.06 0.166 138
IBD status ever, yes vs no 0.55 0.33–0.92 0.024 137
Biliary tract cancer, yes vs no 6.30 3.58–11.09 ,0.001 138
Bilirubin 2.16 1.72–2.71 ,0.001 130
Albumin, per g/L increase 0.87 0.85–0.91 ,0.001 129
ALP 2.29 1.60–3.28 ,0.001 130
AST 1.65 1.26–2.15 ,0.001 130
ALT 1.21 0.91–1.62 0.184 130
Platelet count 0.66 0.45–0.98 0.039 129
APRI score, per point increase 1.39 1.19–1.63 ,0.001 129
INR, per point increase 12.53 3.49–45.00 ,0.001 113
All data shown from the Oslo cohort and part of the data from the Helsinki and combined cohort.
aCalculated in a subset of 64 patients from the Helsinki cohort with available Mayo score and AOM, events n5 12.
bCalculated in a subset of 193 patients with available Mayo score, events n5 72.
cCalculated in a subset of 192 patients with available AOM, events n5 72. Bilirubin, ALP, AST, ALT, and platelet count were transformed by the natural logarithm before
regression analyses because of a right-skewed distribution.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AOM, Amsterdam-Oxford Model for primary sclerosing cholangitis; AST, aspartate aminotransferase; CI,
confidence interval, ELF, enhanced liver fibrosis; HR, hazard ratio; IBD, inflammatory bowel disease; INR, international normalized ratio; LnsCD163, logarithmic
transformed soluble CD163; LnsMR, logarithmic transformed soluble mannose receptor; PSC, primary sclerosing cholangitis; sCD163, soluble CD163; sMR, soluble
mannose receptor; TRC, platelet count.
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with or without features of AIH. Similar results were found
for sMR.
Association between sCD163 and sMR and long-term prognosis
in patients with PSC
In the combined cohort, patients with high sCD163 had lower 8-
year transplant-free survival (35.2%, 95% CI [24.9%–45.7%])
than those with low sCD163 (83.0%, 95% CI [77.2%–87.5%]).
Similarly, those with high sMR had lower eight-year transplant-
free survival (46.2%, 95% CI [32.7%–58.6%]) than those with low
sMR (75.5%, 95% CI [69.4%–80.5%]) (Figure 2). We found
similar results in theOslo cohort alone, but in theHelsinki cohort,
there was no difference in eight-year transplant-free survival
between patients with low and high sMR. The transplant-free
survival was in general lower in the Oslo cohort than in the
Helsinki cohort (see Supplemental Figure 2, Supplementary
Digital Content 1, http://links.lww.com/CTG/A513).
Results from the univariate Cox regressions are listed in
Table 2. sCD163 and sMR showed association with transplant-
free survival in the combined cohort, and so did the Mayo risk
score, ELF test, and AOM (Table 2). We found similar results in
the individual cohorts, except for sMR not being associated with
transplant-free survival in the Helsinki cohort (Table 2).
In multivariate analyses including the novel markers, ELF test
and AOM, neither sCD163 nor sMR were associated with the
outcome in the combined or any of the individual cohorts
(Table 3). Recruitment center was not associated with outcome in
the combined cohort (Table 3).
Prediction of transplant-free survival by sCD163 and sMR in
patients with PSC
AUROC analysis showed good discrimination for sCD163 be-
tween patients with PSC with and without endpoints (death or
LT) after 8-year follow-up in the combined cohort, with an area
under the curve (AUC) of 0.79 (95%CI; 0.74–0.85), whereas sMR
had an AUC of 0.67 (95% CI; 0.61–0.74) (Figure 3, Table 4). The
AUC did not increase when combining sCD163 and sMR with
either Mayo score, ELF test, or AOM (Table 4).
Both sCD163 and sMR performed better in the Oslo cohort
with AUCs of 0.80 and 0.73, respectively, than in the Helsinki
cohort with AUCs of 0.70 and 0.60, respectively. The ELF test
showed equally good discriminatory abilities in both cohorts with
an AUC of 0.82. TheMayo score and AOMalso performed better
in the Oslo cohort (AUC $ 0.80) than in the Helsinki cohort
(AUC, 0.70).
DISCUSSION
Here, we present, for the first time, analyses of the macrophage
activationmarkers sCD163 and sMR in 2 independent cohorts of
patients with PSC. Themain findingswere the increased degree of
macrophage activationwith increasing liver disease severity (liver
parameters, Mayo score, ELF test, and AOM). Furthermore, the
Table 3. Multivariate Cox regression analyses of factors affecting the transplant-free survival in patients with PSC
Oslo cohorta
sCD163, ELF, and AOM sMR, ELF, and AOM
HR 95% CI P Value HR 95% CI P Value
AOM, per point increase 1.77 1.21–2.58 0.003 1.77 1.21–2.59 0.003
ELF test, per point increase 1.51 1.17–1.96 0.002 1.56 1.24–1.95 ,0.001
LnsCD163 1.03 0.54–1.97 0.92 — — —
LnsMR — — — 0.91 0.48–1.73 0.78
Helsinki cohortb
sCD163, ELF, and AOM sMR, ELF, and AOM
HR 95% CI P Value HR 95% CI P Value
AOM, per point increase 0.84 0.30–2.32 0.74 0.72 0.25–2.06 0.54
ELF test, per point increase 2.91 1.42–5.94 0.003 2.62 1.47–4.69 0.001
LnsCD163 0.70 0.17–2.92 0.63 — — —
LnsMR — — — 1.64 0.27–10.13 0.59
Combined cohortc
sCD163, ELF, and AOM sMR, ELF, and AOM
HR 95% CI P Value HR 95% CI P Value
AOM, per point increase 1.65 1.15–2.38 0.007 1.65 1.15–2.37 0.007
ELF test, per point increase 1.66 1.31–2.10 ,0.001 1.66 1.35–2.04 ,0.001
LnsCD163 0.92 0.52–1.63 0.78 — — —
LnsMR — — — 0.89 0.50–1.60 0.70
Center (Oslo 5 reference) 0.64 0.33–1.25 0.19 0.66 0.34–1.27 0.21
aCalculated in a subset of 128 patients with available AOM, events n 5 60.
bCalculated in a subset of 64 patients with available AOM, events n 5 12.
cCalculated in a subset of 192 patients with available AOM, events n 5 72.
AOM, Amsterdam-Oxford Model for primary sclerosing cholangitis; CI, confidence interval; HR, hazard ratio; LnsCD163, logarithmic transformed soluble CD163; LnsMR,
logarithmic transformed soluble mannose receptor; PSC, primary sclerosing cholangitis; sCD163, soluble CD163; sMR, soluble mannose receptor.







markers were associated with prognosis, and for sCD163, the
discriminative performance was similar to that of theMayo score,
ELF test, and AOM in the Oslo cohort of more advanced disease.
Themacrophage activationmarkers, sCD163 and sMR, have not
previouslybeen investigated inpatientswithPSC,butwecontemplate
that most of the measured sCD163 and sMR stem from infiltrating
macrophages in the liver because the median level of sCD163 and
sMR are similar to those previously presented in other chronic in-
flammatory liver diseases (14,16,22). We previously showed that
sCD163reflectsCD163expressionby immunohistochemistry in liver
biopsies (17,21), and levels of sCD163 decrease after treatment in
chronic viral hepatitis B andC,AIH, andnonalcoholic steatohepatitis
(15,16,21,35,36). Moreover, we previously demonstrated a gradient
across the liver in patients with liver cirrhosis and nonalcoholic
steatohepatitis suggesting intrahepatic excretion (16,18,37). Further-
more, a recent study found that the monocyte activation marker
CD14 was elevated in patients with PSC and predicted liver-
transplant-free survival (9). Thus, we believe that the measured
sCD163 and sMR levels reflect liver disease severity and stage in PSC,
also indicated by the relation found to disease pathophysiology (6–8).
PSC is a chronic liver disease primarily affecting the bile ducts,
but as the disease progresses, liver fibrosis and cirrhosis may
develop. In line with this, we observed elevated levels of markers
ofmacrophage activation that correlatedwith disease progression
as estimated by Mayo score, ELF test, AOM, ALP, and bilirubin.
Thus, itmay be suggested thatmacrophage activationmarkers are
elevated in relation to the grade of fibrosis or cirrhosis, and hence
a measure of unspecific liver disease.
On the other hand, PSC-specific characteristics, such as chronic
inflammation in the biliary tree, may stimulate macrophages in the
surrounding area, as supported by elevated numbers of perisinusoidal
macrophages in liver biopsies from patients with PSC compared with
patients with PBC and normal controls (6,7). Furthermore, genome-
wide association studies have identified a single-nucleotide poly-
morphism in the gene coding the macrophage stimulating-1
Figure 3. AUC’s for sCD163, sMR, ALP, ELF test, Mayo score, and AOM in
patients with PSC in discriminating patients experiencing the composite
endpoint (LT or death) or not. ALP, alkaline phosphatase; AOM, Amsterdam-
Oxford model for primary sclerosing cholangitis; AUC, area under the receiver
operating curve; ELF, enhanced liver fibrosis; PSC, primary sclerosing
cholangitis; sCD163, soluble CD163; sMR, soluble mannose receptor.
Table 4. Prediction of clinical outcome in PSC for sCD163 and sMR in the combined cohort
Cut-off AUC 95% CI Sensitivity Specificity PPV NPV
sCD163 2.87 0.79 0.74–0.85 73.9 73.7 54.2 87.0
sMR 0.29 0.67 0.61–0.74 68.2 61.7 42.9 82.2
ELF test 9.64 0.85 0.80–0.90 76.1 79.4 60.9 88.8
Mayo scorea 0.43 0.79 0.73–0.86 65.3 86.0 73.4 80.6
AOMb 1.91 0.78 0.71–0.85 65.2 82.5 69.1 79.8
ALPc 162 0.79 0.73–0.86 81.8 64.9 54.8 87.3
sCD163 1 sMR — 0.79 0.74–0.85 73.9 73.2 53.7 86.9
ELF 1 sCD163 — 0.85 0.80–0.90 77.3 79.4 61.3 89.2
ELF 1 sMR — 0.85 0.80–0.90 77.3 78.5 60.2 89.1
Mayo 1 sCD163a — 0.81 0.74–0.87 63.9 90.1 79.3 80.7
Mayo 1 sMRa — 0.80 0.73–0.86 69.4 81.8 69.4 81.8
AOM 1 sCD163b — 0.80 0.74–0.87 63.8 86.7 74.2 80.0
AOM 1 sMR** — 0.78 0.71–0.85 73.6 74.2 63.1 82.4
aCalculated in 193 patients with available Mayo score.
bCalculated in 192 patients with available AOM.
cCalculated in 225 patients with available ALP.
AUROC analysis for the ability to discriminate between patients with and without endpoint for sCD163, sMR, Mayo score, ELF test and ALP as well as for combinations of
sCD163, sMR, ELF test, Mayo score, and AOM. Cutoff values were determined by Youden index.
ALP, alkaline phosphatase; AOM, Amsterdam-Oxford Model for primary sclerosing cholangitis; AUC, area under the curve; CI, confidence interval; ELF, enhanced liver
fibrosis; NPV, negative predictive value; PPV, positive predictive value; sCD163, soluble CD163; sMR, soluble mannose receptor.
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(MST-1) protein as the strongest non-human leukocyte antigen
risk locus in PSC (38).MST-1 is expressed throughout the liver and
biliary epithelium and is associated with macrophage differentia-
tion and skewing toward the anti-inflammatory M2 phenotype.
The single-nucleotide polymorphism found in PSC makes the
MST-1 protein hypofunctional and hence skews the macrophage
pool toward the proinflammatory M1 phenotype (38), creating a
more proinflammatory milieu. In such, a milieu more macro-
phages are activated andmoreCD163 cleaved and accompanied by
increased sCD163 levels, which may suggest that macrophage ac-
tivation is partly caused by PSC specific characteristics. This bi-
ological hypothesis, however, cannot be investigated in a studywith
a retrospective design, such as the present, andwe cannotmake any
conclusions on whether the levels of macrophage activation
markers reflect PSC-specific characteristics or unspecific measures
of liver disease, such as fibrosis or cirrhosis. To make such con-
clusion, themarkers needs to be further investigated in prospective
studies including genetic testing and liver biopsies.
TheMayo score, the ELF test, andAOMare 3of the best validated
risk assessment tools used in patients with PSC (31,39). The mac-
rophage activation markers investigated here closely correlated with
both the Mayo score, ELF test, and AOM in the Oslo cohort, sug-
gesting a good ability to discriminate between those patients with a
good and a poor prognosis. This was supported by the AUROC
analysis where sCD163 showed similar performance to the Mayo
score, ELF test, and AOM in advanced disease, i.e. the Oslo cohort.
sCD163 was also associated with outcome in the Helsinki cohort
(primarily earlier stage disease), as were the Mayo score and AOM;
however, here, theELF test showedabetterdiscriminatory ability.We
cannot explain why sCD163 and AOM performed poorer in the
Helsinki cohort of patients with earlier stage disease than in the Oslo
cohort. We do, however, speculate that this may be due to a larger
degree of fluctuation of the blood samples included in the scores in
earlier stage disease, whereas the components reflective of fibrosis
included in the ELF test are more stable. Although it is possible that
the differing approaches to ERCP and endoscopic therapy between
the 2 cohortsmayhave affectedour results, it has not been established
whether these differing approaches affect prognosis. Based on our
data, we suggest that sCD163, as the best marker, should be included
in future studies in PSC to further investigate the role ofmacrophage
activation in PSC. We also encourage the inclusion of macrophage
activation markers in prospective studies with repeated measure-
ments to analyze the ability of these markers to reflect, e.g. treatment
response of possible therapies affecting macrophage function.
The data presented here stems from 2well-characterized cohorts of
patients with PSC with complete follow-up of all patients. A large
number of events during the follow-upperiod provided important data
for analyzing the discriminatory and prognostic values of variables. A
weakness of the study is the difference in disease severity between the 2
cohorts. The Oslo cohort represents patients at a referral transplant
center, and therefore, more patients presented with advanced liver
disease and evaluation for liver transplants than in the Helsinki cohort.
However, recruitment center itself, was not associated with outcome in
multivariate Cox regression. Despite stage differences, we were able to
reproduce findings in the 2 independent cohorts and in the combined
cohort. Both cohorts included patients at different stages of disease
progression as indicated by the variable disease duration, Mayo risk
scores, andfibrosis severityasassessedby theELFtest.Hence,webelieve
that the measured levels of sCD163 and sMR are valid and represen-
tative for patients with PSC. Unfortunately, we only have one mea-
surement of the macrophage activation markers at inclusion to the
study. Thus, we do not knowwhether sCD163 and sMR fluctuates like
ALPandothermarkers inPSCandwhether continuousmeasurements
would have improved their prognostic and discriminatory capabilities,
and we cannot conclude anything related to their monitoring abilities.
In conclusion, we showed that macrophage activation markers
are closely correlated with liver disease severity in patients with PSC.
Moreover, sCD163 showeddiscriminatory abilities on the same level
as the Mayo score and ELF test in advanced stage disease, and
sCD163 predicted transplant-free survival in univariate analyses.
This suggests an important role of macrophages in the pathophys-
iologyofPSC, especially in advanceddisease, andwe suggest sCD163
to be explored in interventional studies of patients with PSC as
marker of treatment response.
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Study Highlights
WHAT IS KNOWN
3 Macrophage activation markers are associated with disease
severity and prognosis in multiple liver diseases.
3 In primary sclerosing cholangitis (PSC), markers of prognosis
are highly warranted.
3 Macrophageactivationmarkers, sCD163andmannose receptor
(sMR), have never been investigated in patients with PSC.
WHAT IS NEW HERE
3 Macrophage activation markers correlate with the Enhanced
Liver Fibrosis test, Mayo score, and AOM in PSC.
3 sCD163 is associatedwith risk of death or liver transplantation
in patients with PSC.
TRANSLATIONAL IMPACT
3 Macrophage activation should be studied further in PSC.
3 sCD163 should be included in future PSC trials with repeated
measurements.
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